Solvonis Therapeutics

London, United Kingdom Founded: 2017 • Age: 9 yrs
Novel therapeutics for addiction and mental health disorders are developed.
Request Access

About Solvonis Therapeutics

Solvonis Therapeutics is a company based in London (United Kingdom) founded in 2017 by Victor Bolduev and Anthony Tennyson.. Solvonis Therapeutics has completed 1 acquisition, including AWAKN. Solvonis Therapeutics offers products and services including Novel Medicines and AI-Supported CNS Programmes.

  • Headquarter London, United Kingdom
  • Founders Victor Bolduev, Anthony Tennyson
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Solvonis Therapeutics Plc
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $0 (USD)
    -100
    as on Dec 31, 2024
  • Net Profit
    $-1.99 M (USD)
    49.04
    as on Dec 31, 2024
  • EBITDA
    $-1.89 M (USD)
    25.75
    as on Dec 31, 2024
  • Latest Funding Round
    $1.67 M (USD), Post-IPO

    Oct 16, 2025

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Solvonis Therapeutics

Solvonis Therapeutics is a publicly listed company on the LSE with ticker symbol SVNS in UK, operating in the Producer manufacturing sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: LSE · Ticker: SVNS . Sector: Producer manufacturing · UK

Products & Services of Solvonis Therapeutics

Solvonis Therapeutics offers a comprehensive portfolio of products and services, including Novel Medicines and AI-Supported CNS Programmes. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Medicines for addiction and mental health disorders are developed to address treatment limitations.

AI-supported programmes for CNS compounds are utilized in the discovery of new therapeutics.

Funding Insights of Solvonis Therapeutics

  • Total Funding
  • Total Rounds 2
  • Last Round Post-IPO — $1.7M
  • First Round

    (11 Jul 2025)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2025 Amount Post-IPO - Solvonis Therapeutics Valuation

investors

Jul, 2025 Amount Post-IPO - Solvonis Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by Solvonis Therapeutics

Solvonis Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AWAKN. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
CRO focused on early stage clinical trial research
2020
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Solvonis Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Solvonis Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Solvonis Therapeutics

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Solvonis Therapeutics

Frequently Asked Questions about Solvonis Therapeutics

When was Solvonis Therapeutics founded?

Solvonis Therapeutics was founded in 2017 and raised its 1st funding round 8 years after it was founded.

Where is Solvonis Therapeutics located?

Solvonis Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Who is the current CEO of Solvonis Therapeutics?

Anthony Tennyson is the current CEO of Solvonis Therapeutics. They have also founded this company.

What does Solvonis Therapeutics do?

Solvonis Therapeutics was founded in 2017 in London, United Kingdom. Operations center on the biotechnology sector, where new medicines are developed to treat addiction and mental health disorders. Initial efforts are directed toward post-traumatic stress disorder, addressing gaps in current treatments. Patient outcomes are targeted for improvement, alongside reductions in associated societal and economic impacts. The companys domain is solvonis.com.

What products or services does Solvonis Therapeutics offer?

Solvonis Therapeutics offers Novel Medicines and AI-Supported CNS Programmes.

Is Solvonis Therapeutics publicly traded?

Yes, Solvonis Therapeutics is publicly traded on LSE under the ticker symbol SVNS.

How many acquisitions has Solvonis Therapeutics made?

Solvonis Therapeutics has made 1 acquisition, including AWAKN.

What is Solvonis Therapeutics's ticker symbol?

The ticker symbol of Solvonis Therapeutics is SVNS on LSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available